Are you optimizing
clinical intelligence?

The right data and strategic insights are often elusive. That is why MDCPartners takes deeper dives for our clients in the pharmaceutical and medical industries. By merging our business expertise with unique IT platforms and portals we can fully support your intelligence and business needs for clinical trial optimization, medical expert identification, and regulatory compliance.

Strategic data advances clinical development

MDCPartners is dedicated to providing tools and services to help pharmaceutical companies make better decisions. Our flagship product, ta-Scan, is a web-based data platform that helps users monitor, aggregate, and analyze regulatory data, trial data, and expert profiles. Whether you need to optimize study placement, select research partners, or manage your portfolios, our products and portals will help you bridge the information gaps in today’s competitive clinical research environment.

Learn more about ta-Scan Visit

While ta-Scan offers the premier navigation and data search experience, MDCPartners has additional data visualization tools that can provide support for more specific needs.

CTAR – Custom reporting for ta-Scan

This complementary tool supplements your ta-Scan data searches and analyses by generating customized reports that are automatically updated with each weekly ta-Scan data refresh.
Learn more about CTAR

LifeRhythm – Visualizing data relationships

Another complementary ta-Scan tool is LifeRhythm, which displays data in an appropriate visual context with interdependent variables. So, for example, you can search for the interconnectivity of any leading researcher.
LifeRhythm also provides a quick method for visualizing the origins of scientific papers, so one publication can connect users to others who have presented on the same topic or participated in related trials. LifeRhythm also includes a robust event dashboard, which tracks recent data revisions.
Learn more about LifeRhythm

Alesia – Advanced Gantt charts

This complementary platform allows ta-Scan users to depict specific clinical trial analyses as advanced Gantt charts.
Learn more about Alesia

Are your medical devices meeting standards?

To support manufacturers of medical devices and in vitro diagnostics (IVDs), MDCPartners has developed normScan, a web-based standards tracking tool tailored to your product range. It can also help you obtain regulatory approval for marketing products throughout Europe, and can assist you with a broad spectrum of regulatory issues related to maintaining compliance.

Learn more about normScan Visit

Bring your own data, use our know-how

MDCPartners doesn’t just offer tools for visualizing public data. We also provide tools for depicting external client data merged with information from our public data cloud. So if you have specific needs that surpass the scope of ta-Scan, you can still rely on us for tailor-made data solutions.

Learn more

Latest News & Events

MDCPartners and ta-Scan at Big Data in Precision Medicine 2016 Washington, D.C.

MDCPartners Innovation Partner Big Data in Precision Medicine Washington

Big Data in Precision Medicine

With ESMO 2016 coming to a close in Copenhagen, MDCPartners is getting ready for their next stop: we are this year’s Innovation Partner of the Big Data in Precision Medicine meeting, which will take place in the Capital Hilton in Washington, D.C. on November 1-2, 2016.

This meeting attracts 250-300 senior executives from across the drug development sector including Big Pharma, biotech, leading solution providers, government, healthcare and academia. The meeting addresses the opportunities and challenges of big and real-world data, and how machine learning and cognitive computing can be applied in the context of drug development. View the meeting’s streams and the meeting agenda here.

Private Clinical Trial Data in the Real-World Data Context

On Tuesday November 1 at 9:30 AM, MDCPartners’ Chief Scientific Officer David Cocker will present our findings on “The value case of private pharma clinical trial data in the real-world data context”.

Real-world data (RWD) is generally the term used to refer to any data which is collected outside of randomized clinical trials (RCT). The data can be from sources including patient data from hospitals and clinicians. The premise is that RWD combined with information from RCTs can provide better research outcomes and improved healthcare.

Unfortunately, available clinical trial information data is really not that big. Often it is also dispersed and contradictory, and includes duplicates through multiple entries that are not verified and/or matched. Many transformative actions with data are frequently heralded as a big data panacea long before any analytical conclusion can be applied.

This presentation will explore the challenges faced when approaching the question of clinical trial data merging and its interoperability with public clinical trial data for creating valuable insights for study placement.

Meeting Up

ta-Scan’s data team will be present in Washington, D.C. as well to show the precision medicine experts how our clinical business intelligence software ta-Scan can leverage today’s medical big data challenges.

If you want to learn more about our software solutions, you can meet us personally during the exhibition at booth #1 or make an appointment with CSO David Cocker or Strategic Data Analyst, Oncology Jonathan Crowther.

Share on:
Tweet about this on TwitterShare on LinkedIn
MDCPartners and ta-Scan at ESMO 2016 Copenhagen

Meet the ta-Scan Oncology Team at ESMO 2016 in Copenhagen

European Society for Medical Oncology

Next stop on our bill: the ESMO 2016 Congress in Copenhagen, Denmark on 7-11 October 2016.

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Across disciplines and across cultures, ESMO bridges the gap between researchers, clinicians and patients and unites all stakeholders focused on finding the most effective cancer treatment solutions available today.

ESMO 2016 will continue to build upon the success of past congresses, offering a top-notch scientific and educational programme created by international experts in oncology. View the online meeting programme here.

Meeting up

ta-Scan‘s oncology team will be present in Copenhagen as well to show the oncology society how our clinical business intelligence software ta-Scan can leverage today’s medical oncology data challenges.

If you want to learn more about our software solutions, you can meet us personally during the conference. Just make an appointment with David CockerJonathan Crowther, or Koen Snijders.

Share on:
Tweet about this on TwitterShare on LinkedIn
MDCPartners at Immunotherapy Leaders Berlin 2016

Meet the ta-Scan Team at Immunotherapy Leaders Europe

Immuno-oncology in Berlin

Enjoying the summer, we are also excited about what comes after: in September, the ta-Scan team will be present at Immunotherapy Leaders Europe, the annual meeting for Immuno-Oncologists in Berlin.

Biomarkers for patient selection

Learn how to use our clinical business intelligence portal ta-Scan to boost success rates in immuno-oncology clinical trials through biomarker-driven patient selection from Strategic Analyst Oncology Dr Jonathan Crowther‘s presentation on:

“Biomarker evolution and utility for patient selection in clinical research”

Wednesday, September 21,  2:45 – 3:05 PM
Stream 3: Boosting success rates in immuno-oncology clinical trials
through biomarker-driven patient selection

  • Using the clinical business intelligence platform ta-Scan to track the evolution of immunotherapy biomarkers and improve patient selection resulting in successful clinical research.
  • Analysis of the immuno-oncology biomarker landscape: What are the trending biomarkers and how do they compare across clinical research?
  • Improving on study design, the who and where in clinical research.
    –  Estimation of patient cohorts?
    –  Key opinion leaders in the field?
    –  What benchmarks have been previously established?
  • Geographical site selection
    –  Where are trials primarily taking place?
    –  What countries and locations are suitable for my trial?

Dr Jonathan Crowther

Jonathan Crowther Immunotherapy Europe ta-Scan MDCPartners

Jonathan Crowther is Strategic Analyst Oncology at MDCPartners where he is working on growing oncology-based projects on the ta-Scan platform. Jonathan holds a PhD from the VIB/University of Leuven (Belgium) where he studied the role of large scale deletions in cancer and explored their potential as novel biomarkers of drug response. Jonathan provided bioinformatic analysis and big data solutions to ongoing areas of research, working on large cancer patient data sets such as The Cancer Genome Atlas (TCGA). In this capacity Jonathan significantly contributed to a number of ongoing projects and has published on these topics.

Meeting up

You can also meet us personally at booth #27 to see a live demonstration of our ta-Scan software. Just drop by or make an appointment with David Cocker or Jonathan Crowther.

Share on:
Tweet about this on TwitterShare on LinkedIn


  • ta-Scan's Trial Feasibility Wizard

    More information about ta-Scan's Trial Feasibility Wizard in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Expert Profiling & Exploring Disease Landscapes

    Learn how to use ta-Scan for expert profiling and exploring disease landscapes.

    US Letter Format | A4 Format
  • ta-Scan for Competitive Intelligence & Medical Affairs

    Learn how to use ta-Scan for competitive intelligence and medical affairs in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan for Clinical Trial Planning & Optimization

    Learn how to use ta-Scan for clinical trial planning and optimization in this fact sheet.

    US Letter Format | A4 Format
  • ta-Scan's Research Landscape Comparison Wizard

    More information about ta-Scan's RLC Wizard in this fact sheet.

    US Letter Format | A4 Format

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page